Emerging evidence for the use of atypical antipsychotics in borderline personality disorder

Pharmacopsychiatry

Volumn 38, Issue 1, 2005, Pages 20-23

  Grootens, K P ^a   Verkes, R J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE;

ANXIETY; AUTOMUTILATION; BORDERLINE STATE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EXTRAPYRAMIDAL SYMPTOM; FOLLOW UP; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MENTAL DISEASE; NAUSEA; OPEN STUDY; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; SIDE EFFECT; SOMNOLENCE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BORDERLINE PERSONALITY DISORDER; CLINICAL TRIALS; CLOZAPINE; DIBENZOTHIAZEPINES; HUMANS; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; RISPERIDONE;

EID: 14044266829     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-837767     Document Type: Review

References (26)

1. Bateman AW, Fonagy P. Psychotherapy for severe personality disorder. Article did not do justice to available research data. BMJ 1999; 319(7211): 709-710
2. Bateman AW, Fonagy P. Effectiveness of psychotherapeutic treatment of personality disorder. Br J Psychiatry 2000; 177: 138-143
3. Benedetti F, Sforzini L, Colombo C, Maffei C, Smeraldi E. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 1998; 59: 103-107
4. Bogenschutz MP, George NH. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 2004; 65: 104-109
5. Chengappa KN, Baker RW, Sirri C. The succesful use of clozapine in ameliorating severe self-mutilating in a patient with borderline personality disorder. J Personal Disord 1995; 9: 76-82
6. Chengappa KN, Ebeling T, Kang JS, Levine J, Parepally H. Clozapine reduces severe self mutilation and aggression in psychotic patients with borderline personality disorder. J Clin Psychiatry 1999; 60: 477-484
7. Frankenburg FR, Zanarini MC. Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry 1993; 34: 402-405
8. Friedel RO. Dopamine Dysfunction in Borderline Personality Disorder: A Hypothesis. Neuropsychopharmacology, 2004; in press
9. Goldberg SC, Schulz SC, Schulz PM, Resnick RJ, Hamer RM, Friedel RO. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry 1986; 43: 680-686
10. Grossman R. Psychopharmacologic treatment of patients with borderline personality disorder. Psychiatric Annals 2002; 32: 357-370
11. Hilger E, Barnas C, Kasper S. Quetiapine in the treatment of borderline personality disorder. World J Biol Psychiatry 2003; 4: 2-44
12. Hough DW. Low-dose olanzapine for self-mutilation behavior in patients with borderline personality disorder. J Clin Psychiatry 2001; 62: 296-297
13. Khouzam HR, Donnelly NJ. Remission of self-mutilation in a patient with borderline personality during risperidone therapy. J Nerv Ment Dis 1997; 185: 348-349
14. Lai A. risperiodone in borerline personality disorder. European Neuropsychopharmacology, 14th congress 2001; 11(S3): S 258
15. Linehan MM. Dialectical behavior therapy for borderline personality disorder. Theory and method. Bull Menninger Clin 1987; 51: 261-276
16. Montgomery SA, Montgomery D. Pharmacological prevention of suicidal behaviour. J Affect Disord 1982; 4: 291-298
17. Practice guideline for the treatment of patients with borderline personality disorder. American Psychiatric Association. Am J Psychiatry, 2001; 158 (10 Suppl): 1-52
18. Rocca P, Marchiaro L, Cocuzza E, Bogetto F. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry 2002; 63: 241-244
19. Schulz SC, Camlin KL, Berry SA, Jesberger JA. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry 1999; 46: 1429-1435
20. Schulz SC, Cornelius J, Schulz PM, Soloff PH. The amphetamine challenge test in patients with borderline disorder. Am J Psychiatry 1988; 145: 809-814
21. Soloff PH. Psychopharmacology of borderline personality disorder. Psychiatr Clin North Am 2000; 23: 169-192, ix
22. Soloff PH, Cornelius J, George A, Nathan S, Perel JM, Ulrich RF. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 1993; 50: 377-385
23. Soloff PH, George A, Nathan RS, Schulz PM, Ulrich RF, Perel JM. Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo. Arch Gen Psychiatry 1986; 43: 691-697
24. Swinton M. Clozapine in severe borderline personality. J Forensic Psychiatry 2001; 12: 580-591
25. Szigethy EM, Schulz SC. Risperidone in comorbid borderline personality disorder and dysthymia. J Clin Psychopharmacol 1997; 17: 326-327
26. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2001; 62: 849-854